Detalles de la búsqueda
1.
Complete Remission with Partial Hematological Recovery as a Palliative Endpoint for Treatment of Acute Myeloid Leukemia.
Blood
; 2024 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38728428
2.
Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials.
Blood
; 142(3): 235-243, 2023 07 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37140031
3.
FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.
Oncologist
; 27(10): 892-899, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35983953
4.
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma.
Oncologist
; 27(7): 587-594, 2022 07 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35403693
5.
FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial.
Oncologist
; 27(2): 149-157, 2022 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35641211
6.
FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.
Oncologist
; 27(6): 493-500, 2022 06 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35363318
7.
Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials.
Cytotherapy
; 24(7): 742-749, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35219582
8.
FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.
Pediatr Blood Cancer
; 69(8): e29602, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35561013
9.
Impact of an evolving regulatory landscape on skin cancer drug development in the U.S.
Dermatol Online J
; 28(2)2022 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35670678
10.
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Lancet Oncol
; 22(9): 1230-1239, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34310904
11.
Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy.
Oncologist
; 26(4): 318-324, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33345396
12.
FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Oncologist
; 26(10): 879-886, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34132444
13.
FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib.
Oncologist
; 26(9): 797-806, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33973307
14.
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.
Oncologist
; 26(10): e1786-e1799, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34196068
15.
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
Oncologist
; 26(5): 433-438, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33687763
16.
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.
BJU Int
; 127(4): 435-444, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32969563
17.
US Food and Drug Administration regulatory updates in neuro-oncology.
J Neurooncol
; 153(3): 375-381, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34156585
18.
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Lancet Oncol
; 21(2): 250-260, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31859246
19.
Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy.
Curr Oncol Rep
; 22(11): 116, 2020 08 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-32851542
20.
The Drug-Dosing Conundrum in Oncology - When Less Is More.
N Engl J Med
; 385(16): 1445-1447, 2021 Oct 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34623789